Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure: Design and rationale of the BioMEMS study: Design and rationale of the BioMEMS study
Uloženo v:
| Název: | Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure: Design and rationale of the BioMEMS study: Design and rationale of the BioMEMS study |
|---|---|
| Autoři: | Allach, Y., Barry-Loncq de Jong, M., Clephas, P.R.D., Gent, M.W.F. van, Brunner-La Rocca, H.P., Szymanski, M.K., Halm, V.P. van, Handoko, M.L., Kok, W.E., Asselbergs, F.W., Kimmenade, R.R.J. van, Manintveld, O.C., Mieghem, N.M. van, Beeres, S.L.M.A., Rienstra, M., Post, M.C., Heerebeek, L. van, Borleffs, C.J.W., Tukkie, R., Mosterd, A., Linssen, G.C., Spee, R.F., Emans, M.E., Smilde, T.D., Ramshorst, J. van, Kirchhof, C.J.H.J., Feenema-Aardema, M.W., Fonseca, C.A. da, Heuvel, Mieke van den, Hazeleger, R., Eck, J.W.M. van, Boersma, E., Kardys, I., Boer, R.A. de, Brugts, J.J. |
| Přispěvatelé: | Team Medisch, Circulatory Health |
| Zdroj: | European Journal of Heart Failure, 26, 8, pp. 1736-1744 |
| Informace o vydavateli: | Wiley, 2024. |
| Rok vydání: | 2024 |
| Témata: | Male, Intracardiac pressures, Heart failure, Pulmonary Artery, THERAPY, Risk stratification, Natriuretic Peptide, Brain, Journal Article, TROPONIN-T, Humans, Pulmonary Wedge Pressure, Repeated measurements, Cardiology - Radboud University Medical Center, Aged, Heart Failure, MORTALITY, Middle Aged, Prognosis, 16. Peace & justice, Peptide Fragments, 3. Good health, BRAIN NATRIURETIC PEPTIDE, HOSPITALIZATION, Chronic Disease, Haemodynamic monitoring, Female, Cardiology and Cardiovascular Medicine, Biomarkers |
| Popis: | AimsHeart failure (HF), a global pandemic affecting millions of individuals, calls for adequate predictive guidance for improved therapy. Congestion, a key factor in HF‐related hospitalizations, further underscores the need for timely interventions. Proactive monitoring of intracardiac pressures, guided by pulmonary artery (PA) pressure, offers opportunities for efficient early‐stage intervention, since haemodynamic congestion precedes clinical symptoms.MethodsThe BioMEMS study, a substudy of the MONITOR‐HF trial, proposes a multifaceted approach integrating blood biobank data with traditional and novel HF parameters. Two additional blood samples from 340 active participants in the MONITOR‐HF trial were collected at baseline, 3‐, 6‐, and 12‐month visits and stored for the BioMEMS biobank. The main aims are to identify the relationship between temporal biomarker patterns and PA pressures derived from the CardioMEMS‐HF system, and to identify the biomarker profile(s) associated with the risk of HF events and cardiovascular death.ConclusionSince the prognostic value of single baseline measurements of biomarkers like N‐terminal pro‐B‐type natriuretic peptide is limited, with the BioMEMS study we advocate a dynamic, serial approach to better capture HF progression. We will substantiate this by relating repeated biomarker measurements to PA pressures. This design rationale presents a comprehensive review on cardiac biomarkers in HF, and aims to contribute valuable insights into personalized HF therapy and patient risk assessment, advancing our ability to address the evolving nature of HF effectively. |
| Druh dokumentu: | Article |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 1879-0844 1388-9842 |
| DOI: | 10.1002/ejhf.3303 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/38825743 https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/310476 https://doi.org/10.1002/ejhf.3303 https://pure.eur.nl/en/publications/9696ff20-9736-4290-b168-8f86a5068cba https://doi.org/10.1002/ejhf.3303 https://research.rug.nl/en/publications/ce805b73-8a93-4c77-94c3-31fd859ebe5f https://hdl.handle.net/11370/ce805b73-8a93-4c77-94c3-31fd859ebe5f https://doi.org/10.1002/ejhf.3303 https://cris.maastrichtuniversity.nl/en/publications/32e081cf-203f-4bdb-a343-c2fe777d19a4 https://doi.org/10.1002/ejhf.3303 https://dspace.library.uu.nl/handle/1874/455639 https://pure.amsterdamumc.nl/en/publications/63e481ba-f274-4e68-bc29-4a0203af704f https://doi.org/10.1002/ejhf.3303 https://repository.ubn.ru.nl/handle/2066/310476 https://repository.ubn.ru.nl//bitstream/handle/2066/310476/310476.pdf |
| Rights: | CC BY NC ND |
| Přístupové číslo: | edsair.doi.dedup.....0c141b97613a58cc7060dc21899dcf3e |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | AimsHeart failure (HF), a global pandemic affecting millions of individuals, calls for adequate predictive guidance for improved therapy. Congestion, a key factor in HF‐related hospitalizations, further underscores the need for timely interventions. Proactive monitoring of intracardiac pressures, guided by pulmonary artery (PA) pressure, offers opportunities for efficient early‐stage intervention, since haemodynamic congestion precedes clinical symptoms.MethodsThe BioMEMS study, a substudy of the MONITOR‐HF trial, proposes a multifaceted approach integrating blood biobank data with traditional and novel HF parameters. Two additional blood samples from 340 active participants in the MONITOR‐HF trial were collected at baseline, 3‐, 6‐, and 12‐month visits and stored for the BioMEMS biobank. The main aims are to identify the relationship between temporal biomarker patterns and PA pressures derived from the CardioMEMS‐HF system, and to identify the biomarker profile(s) associated with the risk of HF events and cardiovascular death.ConclusionSince the prognostic value of single baseline measurements of biomarkers like N‐terminal pro‐B‐type natriuretic peptide is limited, with the BioMEMS study we advocate a dynamic, serial approach to better capture HF progression. We will substantiate this by relating repeated biomarker measurements to PA pressures. This design rationale presents a comprehensive review on cardiac biomarkers in HF, and aims to contribute valuable insights into personalized HF therapy and patient risk assessment, advancing our ability to address the evolving nature of HF effectively. |
|---|---|
| ISSN: | 18790844 13889842 |
| DOI: | 10.1002/ejhf.3303 |